Antiplatelet Therapy in 2026: What the New ACC Scientific Statement Changes for Practice

A synthesis of the new consensus document — and what it means for prescribing, deprescribing, and portfolios.

Physician Education & Market Perspective

A new 2026 ACC scientific statement on antiplatelet therapy pulls together, for the first time, guidance that had been scattered across separate acute coronary syndrome, chronic coronary disease, stroke, and peripheral artery disease documents.

The writing committee's stated goal was to give clinicians one framework for the ischemia-versus-bleeding tradeoff that now spans a patient's entire cardiovascular life, not just a single index event.

The single biggest practical shift is a growing comfort with shorter dual antiplatelet therapy courses followed by potent P2Y12 inhibitor monotherapy, rather than the traditional twelve months of combined aspirin and a P2Y12 agent.

Below is a distillation of the actionable changes, paired with the drug and device economics that matter to a physician-investor audience.

Case Vignette

A 68-year-old man is admitted with a non-ST-elevation myocardial infarction and undergoes drug-eluting stent placement to a single mid-vessel lesion.

He has no history of prior bleeding, a hemoglobin of 14 g/dL, and an estimated glomerular filtration rate of 68 mL/min, placing him at low bleeding risk by ARC-HBR criteria.

Under the new statement, a reasonable strategy is aspirin plus ticagrelor for one to three months, followed by ticagrelor monotherapy, rather than a fixed twelve-month dual-therapy course.

If he were instead 78 years old with a recent gastrointestinal bleed, the same statement would steer toward clopidogrel-based dual therapy with earlier deescalation to protect against hemorrhage.

Aspirin for Primary Prevention: A Narrower Lane

The statement reaffirms that routine aspirin for primary prevention in unselected adults is no longer supported, largely because background statin therapy already does much of the protective work aspirin once provided.

Low-dose aspirin may still be reasonable for adults 40 to 70 years old who carry a genuinely elevated ischemic risk and a low bleeding risk, but routine use past age 70 should be avoided.

A meta-analysis of thirteen large trials found a modest cardiovascular benefit (hazard ratio 0.89) offset by a 43% relative increase in major bleeding, with a number needed to harm of 880 for intracranial hemorrhage.

Coronary artery calcium scoring and lipoprotein(a) measurement can help identify the subset of patients in whom the benefit-risk ratio still favors aspirin.

P2Y12 Choice After PCI: Prasugrel's Case Strengthens

For acute coronary syndrome treated with PCI, prasugrel and ticagrelor remain preferred over clopidogrel, but the statement now leans further toward prasugrel where there is no contraindication.

Head-to-head data from ISAR-REACT 5 and the newer TUXEDO-2 trial, reported at the 2025 AHA sessions, both showed lower rates of death, MI, or stroke with prasugrel compared with ticagrelor, without a matching increase in bleeding.

Clopidogrel is still preferred in patients over 75 years old, in those at high bleeding risk, or where cost and access make the more potent agents impractical.

Ischemic risk falls sharply in the first month after an acute event while bleeding risk declines more gradually — the rationale for shifting from dual therapy to P2Y12 monotherapy at one to three months rather than waiting a full year.

Duration of DAPT: The Default Is Shrinking

For chronic coronary disease treated with PCI, six months of aspirin plus clopidogrel remains the default, but one to three months followed by P2Y12 monotherapy is now an accepted alternative in lower-risk patients.

For acute coronary syndrome, twelve months of dual therapy is still the baseline, yet shortened courses of one to three months followed by ticagrelor or prasugrel monotherapy are increasingly supported by trial data such as TWILIGHT, TICO, and TARGET-FIRST.

Clopidogrel-based shortened regimens have not shown the same safety margin; STOPDAPT-2 ACS found a trend toward more ischemic events when clopidogrel monotherapy followed only one to two months of dual therapy.

Very early aspirin withdrawal — within days rather than weeks — has also underperformed, as shown in the NEOMINDSET trial, so the deescalation window matters as much as the destination drug.

Table 1. Default DAPT Duration by Clinical Scenario (2026 ACC Statement)

Clinical Setting	Default Duration	Accepted Shortened Strategy	Preferred Agent(s)
Chronic coronary disease + PCI	6 months	1–3 months, then P2Y12 monotherapy	Clopidogrel; ticagrelor/prasugrel if low bleeding risk
Acute coronary syndrome + PCI	12 months	1–3 months, then P2Y12 monotherapy	Ticagrelor or prasugrel
PAD, post-revascularization	1–6 months	≤1 month before surgical bypass	Clopidogrel or ticagrelor
Minor stroke / high-risk TIA	21 days	Not applicable — fixed short course	Aspirin + clopidogrel
CABG (isolated)	Aspirin monotherapy	DAPT only if high graft-failure risk	Aspirin; clopidogrel alternative

Beyond One Year: Clopidogrel Monotherapy Gains Ground

Perhaps the most striking shift in the document is its treatment of long-term secondary prevention beyond the first year after an event.

Emerging data, reinforced by ten-year follow-up of the HOST-EXAM trial, suggest that clopidogrel monotherapy may offer better ischemic protection with similar or lower bleeding than aspirin monotherapy for chronic coronary disease.

For higher-risk patients with stable coronary or peripheral disease and no prior major bleeding or stroke, low-dose rivaroxaban 2.5 mg twice daily added to aspirin 81 mg daily remains an option, based on the COMPASS trial's reduction in cardiovascular death and total mortality.

Adding a full-dose direct oral anticoagulant to dual antiplatelet therapy, by contrast, has repeatedly produced excess bleeding without proportionate ischemic benefit across APPRAISE-2, ATLAS ACS 2-TIMI 51, and GEMINI-ACS-1.

Four distinct receptor pathways converge on platelet activation; aspirin and P2Y12 inhibitors act on separate pathways, which is why their combination (DAPT) produces additive platelet inhibition.

Drug and Device Economics for the Physician-Investor

Generic clopidogrel now costs as little as $4.50 a month with a GoodRx coupon, which helps explain its durability as the default agent whenever cost, adherence, or bleeding risk favor a less potent option.

Ticagrelor, sold as brand-name Brilinta by AstraZeneca NASDAQ: AZN, now faces generic competition; brand-name 90 mg tablets still run about $462 for a 30-day supply, while generic ticagrelor is available for roughly $23 to $30 with a coupon.

Prasugrel, marketed as Effient by Eli Lilly NYSE: LLY and co-developed with Daiichi Sankyo, is now generically available for about $14 to $20 a month with a coupon, down from several hundred dollars for the brand.

Rivaroxaban, sold as Xarelto by Bayer OTC: BAYRY in partnership with Johnson & Johnson in the United States, has a generic-available 2.5 mg dose priced around $30 with a GoodRx coupon, versus roughly $520 at retail.

Table 2. Antiplatelet and Adjunctive Antithrombotic Agents: Clinical and Market Snapshot

Generic (Brand)	Class	Manufacturer / Ticker	Typical Monthly Cash Price*	Analyst Consensus
Clopidogrel (Plavix)	P2Y12 inhibitor	Generic; originator Sanofi/BMS	~$4.50–$10	N/A (generic)
Ticagrelor (Brilinta)	P2Y12 inhibitor	AstraZeneca AZN	~$23–$30 (generic); ~$462 (brand)	Strong Buy, ~$224 PT
Prasugrel (Effient)	P2Y12 inhibitor	Eli Lilly LLY / Daiichi Sankyo	~$14–$20 (generic)	Buy, ~$1,216 PT
Rivaroxaban (Xarelto)	Factor Xa inhibitor	Bayer BAYRY / J&J	~$30 (2.5 mg generic); ~$520 (brand)	Moderate Buy, ~$12–$14 PT

*Cash prices reflect GoodRx-listed discounts as of early July 2026 and vary by pharmacy and location; insured patients typically pay less.

Special Populations in Brief

In peripheral artery disease, adding low-dose rivaroxaban to aspirin after revascularization reduces major adverse limb events, per the VOYAGER-PAD trial, particularly in patients with prior amputation or polyvascular disease.

In minor ischemic stroke or high-risk TIA, aspirin plus clopidogrel for 21 days followed by monotherapy reduces early recurrent stroke without the bleeding penalty seen with longer dual courses.

Triple therapy combining oral anticoagulation with dual antiplatelet therapy should be avoided whenever possible; the statement favors dropping aspirin within one month of PCI in patients who need an anticoagulant, leaving a P2Y12 inhibitor and a direct oral anticoagulant as the long-term combination.

Bottom Line

The 2026 ACC statement pushes practice toward shorter dual antiplatelet courses followed by potent P2Y12 monotherapy, a narrower and more selective role for aspirin in primary prevention, and a growing preference for clopidogrel monotherapy over aspirin monotherapy beyond the first year after a coronary event.

Genotype-guided or platelet-function-guided deescalation remains optional rather than mandatory, and unguided switching at one month after ACS-PCI appears similarly safe in the available trials.

From an investment standpoint, the shift toward shorter branded P2Y12 exposure and toward generic clopidogrel and rivaroxaban has modest read-through for volume-driven generics manufacturers, while AstraZeneca and Eli Lilly's franchise durability increasingly depends on newer indications and pipeline assets rather than legacy antiplatelet volume.

This content is for physician education only and does not constitute individualized clinical or investment advice; treatment decisions should be individualized, and any securities discussion should be verified against current company disclosures before acting.

References

1. Kumbhani DJ, et al. Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement. JACC.
2. American College of Cardiology. Guidelines and Clinical Policy document library.
3. TCTMD. Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD (TUXEDO-2).
4. GoodRx. Clopidogrel pricing and savings information.
5. GoodRx. Brilinta (ticagrelor) pricing and savings information.
6. GoodRx. Prasugrel (Effient) pricing and savings information.
7. GoodRx. Xarelto (rivaroxaban) pricing and savings information.
8. StockAnalysis.com. AstraZeneca PLC (AZN) financial data.
9. StockAnalysis.com. Eli Lilly and Company (LLY) financial data.
10. StockAnalysis.com. Bayer Aktiengesellschaft (BAYRY) financial data.

This article is intended for physician education and does not constitute clinical practice guidance for any individual patient; treatment decisions require individualized assessment of ischemic and bleeding risk. Ticker symbols, pricing, and analyst data are provided for general informational and educational purposes only, are not investment advice, and should be independently verified; the author is not a licensed financial advisor. Drug pricing reflects publicly listed cash/discount prices at the time of writing and is subject to change.